Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.

Felgenhauer J, Tomino L, Selich-Anderson J, Bopp E, Shah N.

Neoplasia. 2018 Oct;20(10):965-974. doi: 10.1016/j.neo.2018.08.002. Epub 2018 Aug 25.

2.

Danger-Associated Molecular Patterns Derived From the Extracellular Matrix Provide Temporal Control of Innate Immunity.

Frevert CW, Felgenhauer J, Wygrecka M, Nastase MV, Schaefer L.

J Histochem Cytochem. 2018 Apr;66(4):213-227. doi: 10.1369/0022155417740880. Epub 2018 Jan 1.

3.

Navigating your career path in pediatric hematology/oncology: On and off the beaten track.

Zweidler-McKay PA, Hogan MJ, Jubran R, Black V, Casillas J, Harper J, Malempati S, Margolin J, Felgenhauer J, Sakamoto KM, Franklin J, Shah M, Seibel N, Buchanan G, Vaiselbuh SR, Hastings C, Hilden J, Stork LC.

Pediatr Blood Cancer. 2016 Oct;63(10):1723-30. doi: 10.1002/pbc.26094. Epub 2016 Jun 13. No abstract available.

PMID:
27295503
4.

Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.

Mascarenhas L, Felgenhauer JL, Bond MC, Villaluna D, Femino JD, Laack NN, Ranganathan S, Meyer J, Womer RB, Gorlick R, Krailo MD, Marina N.

Pediatr Blood Cancer. 2016 Mar;63(3):493-8. doi: 10.1002/pbc.25837. Epub 2015 Nov 18.

5.

Identification of Discrete Prognostic Groups in Ewing Sarcoma.

Karski EE, McIlvaine E, Segal MR, Krailo M, Grier HE, Granowetter L, Womer RB, Meyers PA, Felgenhauer J, Marina N, DuBois SG.

Pediatr Blood Cancer. 2016 Jan;63(1):47-53. doi: 10.1002/pbc.25709. Epub 2015 Aug 10.

6.

Regulatory barriers to clinical trial enrollment of adolescent and young adult oncology patients.

Felgenhauer J, Hooke MC.

Pediatrics. 2014 Jun;133 Suppl 3:S119-22. doi: 10.1542/peds.2014-0122H.

PMID:
24918210
7.

Children's Oncology Group's 2013 blueprint for research: adolescent and young adult oncology.

Freyer DR, Felgenhauer J, Perentesis J; COG Adolescent and Young Adult Oncology Discipline Committee.

Pediatr Blood Cancer. 2013 Jun;60(6):1055-8. doi: 10.1002/pbc.24431. Epub 2012 Dec 19. Review.

8.

A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893.

Felgenhauer JL, Nieder ML, Krailo MD, Bernstein ML, Henry DW, Malkin D, Baruchel S, Chuba PJ, Sailer SL, Brown K, Ranganathan S, Marina N.

Pediatr Blood Cancer. 2013 Mar;60(3):409-14. doi: 10.1002/pbc.24328. Epub 2012 Oct 12.

9.

Increasing diversity in pediatric hematology/oncology.

Frugé E, Lakoski JM, Luban N, Lipton JM, Poplack DG, Hagey A, Felgenhauer J, Hilden J, Margolin J, Vaiselbuh SR, Sakamoto KM.

Pediatr Blood Cancer. 2011 Jul 15;57(1):147-52. doi: 10.1002/pbc.22977. Epub 2011 Jan 31.

10.

Localized purpura associated with lamotrigine.

Amlie-Lefond CM, Felgenhauer JL, Leong AD.

Pediatr Neurol. 2006 Sep;35(3):227-8.

PMID:
16939867
11.

Infantile myofibromatosis of the posterior fossa.

Chapman PR, Judd CD, Felgenhauer JL, Gruber DP, Mornin D.

AJR Am J Roentgenol. 2005 Apr;184(4):1310-2. No abstract available.

PMID:
15788615
12.

Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.

Thomson B, Park JR, Felgenhauer J, Meshinchi S, Holcenberg J, Geyer JR, Avramis V, Douglas JG, Loken MR, Hawkins DS.

Pediatr Blood Cancer. 2004 Oct;43(5):571-9.

PMID:
15382275
13.

Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.

Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH, Avramis VI.

Clin Cancer Res. 2004 Aug 15;10(16):5335-41.

14.

Intensive induction chemotherapy and delayed irradiation in the management of parameningeal rhabdomyosarcoma.

Smith SC, Lindsley SK, Felgenhauer J, Hawkins DS, Douglas JG.

J Pediatr Hematol Oncol. 2003 Oct;25(10):774-9.

PMID:
14528099
15.

Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.

Hawkins DS, Felgenhauer J, Park J, Kreissman S, Thomson B, Douglas J, Rowley SD, Gooley T, Sanders JE, Pendergrass TW.

Cancer. 2002 Sep 15;95(6):1354-65.

16.

No excess of early onset cancer in family members of Wilms tumor patients.

Felgenhauer JL, Barce JM, Benson RL, Nan B, Olson JM, Breslow NE.

Cancer. 2001 Sep 15;92(6):1606-12.

PMID:
11745239
17.

Successful dose-intensive treatment of desmoplastic small round cell tumor in three children.

Kurre P, Felgenhauer JL, Miser JS, Patterson K, Hawkins DS.

J Pediatr Hematol Oncol. 2000 Sep-Oct;22(5):446-50.

PMID:
11037858
18.

Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas.

Felgenhauer J, Hawkins D, Pendergrass T, Lindsley K, Conrad EU 3rd, Miser JS.

Med Pediatr Oncol. 2000 Jan;34(1):29-38.

PMID:
10611582
20.

Elevated zinc protoporphyrin associated with thalassemia trait and hemoglobin E.

Graham EA, Felgenhauer J, Detter JC, Labbe RF.

J Pediatr. 1996 Jul;129(1):105-10.

PMID:
8757569
21.

Relationship between epidemiologic risk factors and clinicopathologic findings in the sudden infant death syndrome.

Haas JE, Taylor JA, Bergman AB, van Belle G, Felgenhauer JL, Siebert JR, Benjamin DR.

Pediatrics. 1993 Jan;91(1):106-12.

PMID:
8416472

Supplemental Content

Loading ...
Support Center